Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...

The lifetime risk of an unexpected and sudden death from a cardiovascular cause in the absence of pre-existing heart disease—known as sudden cardiac death—is more than 4 times higher for people with ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

No individual antipsychotic was associated with better cognitive outcomes than placebo in patients with schizophrenia spectrum disorders (SSD), according to a systematic review an ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

A comprehensive EU-wide mental health strategy is essential to tackle the region’s growing mental health crisis. Prioritising ...

The results have been met with excitement, especially since substantial portions of the schizophrenia population don’t respond to or stay on other therapies. Yet doctors, while eager to have another ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...